Show simple item record

Calcification of polyurethanes implanted subdermally in rats is enhanced by calciphylaxis

dc.contributor.authorJoshi, Ravi R.en_US
dc.contributor.authorUnderwood, Thomasen_US
dc.contributor.authorFrautschi, Jack R.en_US
dc.contributor.authorPhillips, Richard E.en_US
dc.contributor.authorSchoen, Frederick J.en_US
dc.contributor.authorLevy, Robert J.en_US
dc.date.accessioned2006-04-28T16:35:49Z
dc.date.available2006-04-28T16:35:49Z
dc.date.issued1996-06en_US
dc.identifier.citationJoshi, Ravi R.; Underwood, Thomas; Frautschi, Jack R.; Phillips, Richard E.; Schoen, Frederick J.; Levy, Robert J. (1996)."Calcification of polyurethanes implanted subdermally in rats is enhanced by calciphylaxis." Journal of Biomedical Materials Research 31(2): 201-207. <http://hdl.handle.net/2027.42/38012>en_US
dc.identifier.issn0021-9304en_US
dc.identifier.issn1097-4636en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/38012
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8731208&dopt=citationen_US
dc.description.abstractCalcification complicates the use of the polymer polyurethane in cardiovascular implants. To date only costly experimental circulatory animal models have been useful for investigating this disease process. In this paper we report that polyurethane calcification in rat subdermal implants is enhanced by overdosing with a vitamin-D analog. The calcification-prone state, known as calciphylaxis, was induced in 4-week old rats by oral administration of a vitamin-D analog, dihydrotachysterol. We studied two commercially available polyurethanes (Biomer® and Mitrathane®) and two proprietary polyurethanes (PEU-2000 and PEU-100). PEU-100 is unique because it is derivatized with ethanehydroxy-bisphosphonate (EHBP) for calcification resistance. Polyurethane calcium and phosphate levels and morphological changes due to calciphylaxis were compared with those of control rat subdermal explants in 60-day studies. Increased polyurethane mineralization was observed due to calciphylaxis with 60-day rat subdermal explants of Biomer®, Mitrathane®, and PEU-2000 (calcium levels, respectively, 4.13 ± 0.56, 18.61 ± 2.73, and 3.37 ± 0.22 μg/mg, mean ± standard error) as compared to control explants (calcium levels, respectively, 1.22 ± 0.1, 12.57 ± 0.86, and 0.20 ± 0.86 μg/mg). The study also demonstrated that with 60-day implants calciphylaxis had no side effects on somatic growth and serum calcium levels. Explant surface morphology of these polyurethane explants examined by scanning electron microscopy, back scattering electron imaging coupled with energy dispersive X-ray spectroscopy, and light microscopy demonstrated the presence of predominantly surface-oriented calcification. PEU-100, derivatized with 100 n.moles/mg of EHBP, resisted calcification with explant calcium levels 0.51 ± 0.01 (calciphylaxis) and 0.38 ± 0.01 (control) μg/mg. It is concluded that calciphylaxis enhances superficial polyurethane calcification in rat subdermal implants and that an EHBP-modified polyurethane resists calcification despite calciphylaxis. Rat subdermal implants using calciphylaxis may be generally useful for evaluating the calcification potential of various biomedical polymers. © 1996 John Wiley & Sons, Inc.en_US
dc.format.extent912943 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherJohn Wiley & Sons, Inc.en_US
dc.subject.otherChemistryen_US
dc.subject.otherPolymer and Materials Scienceen_US
dc.titleCalcification of polyurethanes implanted subdermally in rats is enhanced by calciphylaxisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbsecondlevelBiomedical Engineeringen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pediatrics, Communicable Diseases, and Pharmaceutics, The University of Michigan, Ann Arbor, Michigan 48109en_US
dc.contributor.affiliationumDepartment of Pediatrics, Communicable Diseases, and Pharmaceutics, The University of Michigan, Ann Arbor, Michigan 48109en_US
dc.contributor.affiliationumDepartment of Pediatrics, Communicable Diseases, and Pharmaceutics, The University of Michigan, Ann Arbor, Michigan 48109 ; R-5014, Kresge II, The University of Michigan Medical School, Annen_US
dc.contributor.affiliationotherCarboMedics, 1300-B, East Anderson Lane, Austin, Texas 78752-1793en_US
dc.contributor.affiliationotherCarboMedics, 1300-B, East Anderson Lane, Austin, Texas 78752-1793en_US
dc.contributor.affiliationotherDepartments of Pathology, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115en_US
dc.identifier.pmid8731208en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/38012/1/6_ftp.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1002/(SICI)1097-4636(199606)31:2<201::AID-JBM6>3.0.CO;2-Ren_US
dc.identifier.sourceJournal of Biomedical Materials Researchen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.